Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy. The company is hoping its pill will be approved as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Novo Nordisk also […]
Glooko, Novo Nordisk team up for connected insulin pens
Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able […]
Abbott, Novo Nordisk ink deal for digital diabetes tools
Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system. The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as […]
Study: Researchers develop ingestible capsule for insulin delivery
A team of researchers from MIT developed an ingestible, blueberry-sized capsule that can deliver insulin orally. In animal models, the capsule lowered blood sugar levels and performed comparably with the traditional route of insulin delivery – injections. The capsule features a small needle made of freeze-dried, compressed insulin. The needle is attached to a compressed […]
Pharma stocks fall as Rep. Cummings launches drug pricing investigation
Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will […]
Novo Nordisk partners with Flex for digital diabetes management tools
Flex (NSDQ:FLEX) today announced a partnership with Novo Nordisk (NYSE:NVO) to develop digital diabetes management tools using Flex’s BrightInsight IoT platform. Novo Nordisk plans to use Flex’s BrightInsight system to build and manage connected medical devices and the corresponding data. The company’s IoT platform is designed to enable organizations to develop digital health devices while remaining […]
Anthem, Novo Nordisk team up for real-world diabetes drug study
Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes. “Because the Sepra […]
Europe OKs Novo Nordisk’s Fiasp for Insulet’s Omnipod
Insulet (NSDQ:PODD) said today that its Omnipod insulin management system is available in Europe for use with Novo Nordisk‘s (NYSE:NVO) Fiasp fast-acting insulin aspart. Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet. “The addition of Fiasp for use […]
Novo Nordisk exec: In the digital age, it’s not enough to have a better molecule
Much of Dr. Todd Hobbs’ life has centered around diabetes – he was diagnosed with Type I diabetes roughly 30 years ago and now he is the father of a child with diabetes. At his Kentucky-based primary care practice, he took on diabetic patients and helped manage their care. And when he made the jump […]
Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech
Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system. The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate […]
- 1
- 2
- 3
- …
- 7
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn